From 5967dd0b6ae528c738db88f600ed23b4a9e3a779 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 15 Mar 2026 19:15:14 +0000 Subject: [PATCH] extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes Pentagon-Agent: Ganymede --- ... net cost impact inflationary through 2035.md | 6 ++++++ ...ney-cardiovascular-and-metabolic-endpoints.md | 6 ++++++ ...-creating-largest-per-patient-cost-savings.md | 6 ++++++ ...ejm-flow-trial-semaglutide-kidney-outcomes.md | 16 +++++++++++++++- 4 files changed, 33 insertions(+), 1 deletion(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 787d6d273..a93f0e3fd 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -29,6 +29,12 @@ Real-world persistence data from 125,474 commercially insured patients shows the The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category. + +### Additional Evidence (extend) +*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-15* + +FLOW trial's kidney protection data strengthens the downstream savings argument: slowing kidney decline by 1.16 mL/min/1.73m2 annually could delay or prevent dialysis ($90K+/year per patient). CKD progression to ESRD represents the highest per-patient cost savings opportunity for GLP-1s, potentially offsetting chronic medication costs in capitated payment models. However, no cost-effectiveness analysis was included in the trial publication. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 1222d36b5..ceee9c165 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr - Nature Medicine: additive benefits with SGLT2 inhibitors - First GLP-1 to receive FDA indication for CKD in T2D patients + +### Additional Evidence (extend) +*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-15* + +FLOW trial demonstrated cardiovascular death reduction of 29% (HR 0.71, 95% CI 0.56-0.89) and 18% lower major cardiovascular events in a kidney-focused trial, suggesting multi-organ benefits are even broader than expected. Separate Nature Medicine analysis shows additive benefits when used with SGLT2 inhibitors, indicating complementary mechanisms across drug classes. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 5299ec097..0906ebd39 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, - FDA indication expansion to T2D patients with CKD (2024) - Dialysis cost benchmark: $90K+/year per patient + +### Additional Evidence (confirm) +*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-15* + +FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), kidney-specific components HR 0.79, and annual eGFR slope less steep by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early for efficacy at prespecified interim analysis. FDA subsequently expanded Ozempic indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM. + --- Relevant Notes: diff --git a/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md b/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md index 4ba699c0a..5697502c1 100644 --- a/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md +++ b/inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md @@ -7,9 +7,13 @@ date: 2024-05-29 domain: health secondary_domains: [] format: paper -status: unprocessed +status: enrichment priority: high tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection] +processed_by: vida +processed_date: 2026-03-15 +enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -38,3 +42,13 @@ Additive benefits when used with SGLT2 inhibitors (separate analysis in Nature M PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Kidney protection is where GLP-1 downstream savings are largest per-patient — dialysis prevention is the economic mechanism most favorable to the VBC cost-saving thesis EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for capitated payers, not just the clinical endpoint + + +## Key Facts +- FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease +- Median follow-up was 3.4 years before early stopping +- Primary composite endpoint showed HR 0.76 (P=0.0003) for major kidney disease events +- Cardiovascular death HR 0.71 (95% CI 0.56-0.89) +- Annual eGFR slope difference: 1.16 mL/min/1.73m2 (P<0.001) +- FDA expanded semaglutide (Ozempic) indications to include T2D patients with CKD following this trial +- Dialysis costs approximately $90K+/year per patient in the US